In8Bio (INAB) Total Non-Current Liabilities (2020 - 2026)

In8Bio has reported Total Non-Current Liabilities for 7 years, with the latest figure at $1.3 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 56.31% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 56.31% YoY) and the FY2025 annual result came in at $1.6 million, down 53.8% from the prior year.
• Total Non-Current Liabilities retreated to $1.3 million in Q1 2026 per INAB's latest filing, from $1.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $4.5 million in Q4 2022 and troughed at $1.3 million in Q1 2026.
• A 5-year average of $3.0 million and a median of $3.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities jumped 185.77% in 2023, then plunged 56.31% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $4.5 million in 2022, then dropped by 24.66% to $3.4 million in 2023, then grew by 0.12% to $3.4 million in 2024, then tumbled by 53.8% to $1.6 million in 2025, then decreased by 15.16% to $1.3 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.3 million, $1.6 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.